Back to ALL Research Publications
Research Category: Wound Sampling, Chronic Wounds
Point-of-care fluorescence imaging predicts the presence of pathogenic bacteria in wounds: a clinical study
References
MY Rennie, PhD1; L Lindvere-Teene, MSc1; K Tapang, MD2; R. Linden, MD2.
1MolecuLight Inc., Toronto, ON, Canada.
2Judy Dan Research and Treatment Centre, Ontario Wound Care Inc., North York, ON, Canada.
Ready to see the difference?
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
Global
USA
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.
References
MY Rennie, PhD1; L Lindvere-Teene, MSc1; K Tapang, MD2; R. Linden, MD2.
1MolecuLight Inc., Toronto, ON, Canada.
2Judy Dan Research and Treatment Centre, Ontario Wound Care Inc., North York, ON, Canada.